Trials / NCT02670980
Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy
Completed N/A Retinal implant
- Sponsor
- Science Corporation
- Treatment
- Intelligent Retinal Implant System
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Cone Rod Dystrophy, Choroideremia
- Ages
- 25 Years to no upper limit
- Enrollment
- 10 participants
- Started
- 2016-01
- Main results expected
- 2019-05
- Results posted
- Not yet
- Record last updated
- 2019-05-29
What the study is testing
This study evaluates the safety and effectiveness of the Intelligent Retinal Implants System (IRIS V2). Blind patient suffering from Retinitis Pigmentosa, Cone Rod Dystrophy, or Choroideremia are implanted with an Intelligent Retinal Implant Systeme. All subjects undergo ophthalmological examinations in predefined intervals after implantation. Ophthalmological examinations include funduscopy, slit lamp examination and OCT. All adverse events are recorded and analyzed. Efficacy is measured using functional vision and visual function tests before and after implantation as well as with the system on and system off.
Where it runs
Austria (1)
- Medical University of Graz, Graz
France (3)
- Clinique Ophtalmologique du CHU de Nantes, Nantes
- CHU Nimes, Service Ophtalmologie (France)/ Hopital Gui de Chauliac, CHU Montpelier, (France), Nîmes
- Hopital des Quinze Vingts/Fondation Ophtalmologique A. De Rothschild, Paris
Germany (3)
- Dept. of Ophthalmology, University of Bonn, Bonn
- Universitäts KlinikumKlinik für Augenheilkunde Freiburg, Freiburg im Breisgau
- Klinik und Poliklinik für Augenheilkunde Hamburg -Eppendorf, Hamburg
Spain (1)
- Instituto de Microcirugia Ocular, Barcelona
United Kingdom (1)
- Moorfields Eye Hospital, London